title: Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
abstract: OBJECTIVE
  To investigate the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI) in women with polycystic ovary syndrome (PCOS) and its correlation with various metabolic, hormonal and hemostatic parameters.
  
  
  METHODS
  Forty-eight women with PCOS and 43 age- and BMI-matched ovulatory controls were recruited during a 20-month study period. Blood samples were drawn for all tests, which included plasma lipids and lipoproteins, reproductive hormones, glucose, insulin, TAFI antigen concentration, plasminogen activator inhibitor-1 (PAI-1) activity, fibrinogen concentration, thrombomodulin, thrombin-antithrombin (TAT) complexes, D-dimer, Protein C Antigen, Protein S Antigen, Antithrombin III (AT III) and activated protein C (APC) resistance.
  
  
  RESULTS
  Plasma TAFI levels of PCOS patients were found to be significantly higher than in healthy controls (93.8%+/-30.6%vs. 79.8% +/- 22.4%, p < 0.05). Plasma levels of D-dimer, AT III, PAI-1 and thrombomodulin were also significantly higher in women with PCOS compared with healthy controls. All the other hemostatic parameters (including TAT complexes; Protein C; APC; and Protein S) were comparable between the two study groups.
  
  
  CONCLUSIONS
  This study showed that plasma levels of TAFI, PAI-1, D-dimer, AT III and thrombomodulin were significantly increased in women with PCOS compared with age- and BMI-matched controls.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Süleyman Demirel University, Isparta, Turkey. baha@med.sdu.edu.tr
authors.forename: Baha
authors.initials: B
authors.lastname: Oral
authors.forename: Betül
authors.initials: B
authors.lastname: Mermi
authors.forename: Müfide
authors.initials: M
authors.lastname: Dilek
authors.forename: Güçhan
authors.initials: G
authors.lastname: Alanoğlu
authors.forename: Recep
authors.initials: R
authors.lastname: Sütçü
mesh_terms: D000328:Adult; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation / Q000502:physiology*; D015992:Body Mass Index; D025901:Carboxypeptidase B2 / Q000097:blood*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006728:Hormones / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D010447:Peptide Hydrolases / Q000097:blood; D010865:Pilot Projects; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood*; D011486:Protein C / Q000378:metabolism; D017293:Protein S / Q000378:metabolism; D018180:Thrombomodulin / Q000097:blood; D055815:Young Adult
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D006728:Hormones; D008055:Lipids; D017395:Plasminogen Activator Inhibitor 1; D011486:Protein C; D017293:Protein S; C051321:SERPINE1 protein, human; D018180:Thrombomodulin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D010447:Peptide Hydrolases; D025901:Carboxypeptidase B2